Q4 2021 Results
Company overview
Pharmaceuticals
Participants
Financial performance
Oncology
Innovation: Pipeline overview
Novartis pipeline in Phase 1 (1 of 2)
Financial review
Conclusion
Oncology
Code
AAA603
AAA817
ADPT01
ADPT03
DFF332
DKY709
HDM201
IAG933
Name
177Lu-NeoB
Ac-PSMA-617
ADPT01
ADPT03
DFF332
DKY709 + spartalizumab
HDM201 + MBG453, venetoclax
IAG933
JBH492
JDQ443
JEZ567
LXF821
JBH492
JDQ443
JEZ567
KAZ954
KAZ954
LXF821
LXH254
LXH254
MAK683
MBG453
MCM998
MIK665
NIS793
MAK683
sabatolimab
MCM998, LXG250
MIK665
NIS793, spartalizumab
NIZ985, spartalizumab
NZV930, spartalizumab, NIR178
NIZ985
NZV930
PDR001
PHE885
PHE885
TNO155
TNO155
VAY736
VOB560
VPM087
WNT974
WVT078
YTB323
spartalizumab
ianalumab + ibrutinib
VOB560
gevokizumab
WNT974+ spartalizumab
WVT078
YTB323
Mechanism
Radioligand therapy target GRPR
Radioligand therapy target PSMA
BCL11A
HIF2A inhibitor
Novel immunomodulatory agent
MDM2 inhibitor
KRAS Inhibitor
CD123 CAR-T
EGFR CAR-T
CRAF inhibitor
EED inhibitor
TIM3 antagonist
BCMA CAR-T, CD19 CAR-T
MCL1 inhibitor
TGFB1 inhibitor
IL-15 agonist
CD73 antagonist
PD1 inhibitor
BCMA cell therapy
SHP2 inhibitor
BAFF-R inhibitor
IL-1 beta antagonist
Porcupine inhibitor
CD19 CAR-T
Indication(s)
Multiple solid tumors.
Metastatic castration-resistant prostate cancer
Colorectal cancer (combos)
Sickle cell anemia
Renal cell carcinoma
Cancers
Haematological malignancy.
Mesothelioma
Haematological malignancy
KRAS G12C mutated solid tumors
Acute myeloid leukaemia
Solid tumors
Glioblastoma multiforme
NSCLC (combos)
Cancers
Low risk myelodysplastic syndrome
Multiple myeloma
Acute myeloid leukaemia (combo)
Solid tumors
Solid tumors
Solid tumors
Solid tumors (combo)
Multiple Myeloma
Solid tumors (combo)
Solid tumors (combo)
Haematological malignancy
Cancers
Colorectal cancer, 1st line
Solid tumors
Multiple myeloma
DLBCL and adult ALL
59 Investor Relations | Q4 2021 Results
Appendix
Innovation: Clinical trials
32 lead indications
Lead indication
NOVARTIS | Reimagining MedicineView entire presentation